Podcasts

Episode 46 | Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy

Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC patients on TKI therapy.

Episode Summary

We have witnessed incredible advances in therapy since ALK was discovered in 2007, starting from the pivotal PROFILE 1001 study of crizotinib in advanced ALK positive NSCLC to present day where we now have five approved targeted agents, with increasing potency, selectivity and CNS activity with each successive generation of drug. Despite these advances in therapy, the emergence of treatment resistance in the TKI still remains one of greatest challenges in the clinic. Our TOGA podcast panel discuss the clinical and genetic factors affecting treatment choice, sequencing and resistance patterns, including oligoprogression and local therapy considerations.

Show Hosts

Dr Rebecca Tay, Medical Oncologist at Royal Hobart Hospital and ICON Hobart
Professor Ben Solomon, Medical Oncologist at Peter MacCallum Cancer Centre & Board member, Scientific Chair of TOGA
Associate Professor Michael Ng, Radiation Oncologist at GenesisCare St Vincents Hospital Melbourne and Head of Stereotactic Radiotherapy at GenesisCare Victoria

References

CROWN
Gomez paper denovo oligomet SABR
Kroeze – concurrent systemic therapy + SABR consensus
Tsai Curb trial RCT for oligoprogression

Play Episode 46 | Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy

More Podcasts

75 – The Evolving Landscape of ROS1-positive NSCLC

Podcasts
September 4, 2026

Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong,

74 – Prof Zarnie Lwin OAM: Mentorship, Research, and the Future of Lung Cancer Treatment

Podcasts
August 28, 2026

Host A/Prof Mel Moore interviews Prof Zarnie Lwin OAM, University of Queensland; Medical Oncologist at Royal Brisbane and Women’s Hospital and The Prince Charles Hospital.

73 – Smoking Stigma and Lung Cancer Care in the Screening Era

Podcasts
August 14, 2026

A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer.

72 – Dr Jazmin Eckhaus: Robotic Innovations and Ethics in Thoracic Surgery

Podcasts
July 31, 2026

Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.

71 – Immunotherapy in Thoracic Cancers: Applying Broad IO Access Across Thoracic Malignancies

Podcasts
June 26, 2026

Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.

70 – Immunotherapy in Thoracic Cancers: From Indication-Based to Biology-Driven

Podcasts
June 19, 2026

Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.